Human ASIC1a Channel EZCells™
The ASIC1a gene encodes the pore-forming subunit of a proton-gated, non-selective cation channel. ASIC1a channels expressed in neurons are therapeutic targets for treatment of pain and depression. Sy...
ChanTest Corporation
ChanTest has the world's largest library of validated human ion channel assays and a growing portfolio of GPCR and transporter targets to serve the needs of its pharmaceutical and biotech customers.
From functional screens for profiling drug candidates or ranking within profiles during the drug-discovery process to a complete set of in vitro GLP and non-GLP services for preclinical cardiac risk assessment, ChanTest works in partnership with customers to cost-effectively speed the drug discovery and development process, and ultimately to help make better, safer drugs.
For more information, visit us at www.chantest.com.
Human HCN4 Channel EZCells™
The HCN4 gene encodes the pore-forming subunit of a hyperpolarization-gated, cyclic nucleotide-sensitive, non-selective cation channel. HCN4 channels expressed in the heart contribute to the pacemaker...
Human KvLQT1/minK Potassium Channel EZCells™
The human KCNQ1 gene encodes the pore-forming subunit of a voltage-gated potassium channel. Co-expression with minK, an auxiliary subunit, recapitulates native function in heterologous expression (CHO...
Action Potential Duration (APD) Testing on hESC-Derived Cardiomyocytes
Evaluate compounds in human stem cell-derived, ventricular-type cardiomyocytes. Effects on action potential parameters are evaluated in single human cardiomyocytes using patch-clamp recording Benefits...
Ion Channel Cell-Based Assays
Functional cell-based assays provide more physiologically useful information compared to binding and non-cellular assays. ChanTest offers cell-based assays to over 90 ion channel targets for screeni...
Browse Products by Field
ChanTest has the world's largest library of validated human ion channel assays and a growing portfolio of GPCR and transporter targets to serve the needs of its pharmaceutical and biotech customers.
From functional screens for profiling drug candidates or ranking within profiles during the drug-discovery process to a complete set of in vitro GLP and non-GLP services for preclinical cardiac risk assessment, ChanTest works in partnership with customers to cost-effectively speed the drug discovery and development process, and ultimately to help make better, safer drugs.
For more information, visit us at www.chantest.com.